Instrumentation Laboratory Achieves Record Sales in 2010

BEDFORD, Mass., March 22, 2011 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced total worldwide sales in 2010 of Euro 474.2 million ($644.9 million US). This represents 11.5% growth v. previous year in current, and 10.3% in local currencies.  In the Company's two major business segments, Critical Care and Hemostasis Diagnostics, worldwide growth in current currencies was 13% (11.9% in local currencies) and 9.7% (8.9% in local currencies), respectively.  

(Logo:  http://photos.prnewswire.com/prnh/20100803/NE44435LOGO )

"We continued our robust growth trajectory in 2010, despite continued economic pressure in the healthcare industry," said Josep Manent, Chief Executive Officer at IL.  "Our products offer customers tremendous time-and cost-efficiencies, key benefits in these times of reduced hospital budgets and staff."  

Innovative new product offerings drove growth on both the Hemostasis and Critical Care sides of the business.  

In 2010, the Company launched the ACL TOP® 700 and ACL TOP 700 CTS Hemostasis Testing Systems.  These analyzers joined other members of the ACL TOP Family, including the ACL TOP 700 LAS and ACL TOP 500 CTS, to offer hemostasis laboratories "Testing Process Automation" and complete standardization.  Additionally, the new ACL AcuStar™ system, the first automated, random-access chemiluminescent analyzer dedicated to Hemostasis specialty testing, was launched in Europe.  It is exceptionally easy to use and offers maximum efficiency.  

For the past eight years, the comprehensive HemosIL® line of reagents has consistently dominated the market with the most sophisticated assays for the diagnosis management and monitoring of Hemostasis disorders.  IL continued this trend in 2010 with double digit growth in all key areas, most notably, with D-Dimer and specialty assays, such as Thrombophilia Screening and Bleeding Disorders reagents.  The introduction of several key new assays, including HemosIL Liquid Heparin assay for monitoring unfractionated and low-molecular weight heparin, and the European release of the HemosIL HIT-Ab assay for ACL TOP systems, solidified IL's position as the innovation leader in Hemostasis testing solutions.  Further, the HemosIL AcuStar anti-phospholipid syndrome (APS) panel, including HemosIL AcuStar aCL IgG & IgM and HemosIL AcuStar B2GPI IgG & IgM, received 510(K) clearance from the FDA.  These assays, along with the Lupus Anticoagulant tests on the ACL TOP Systems, complete the panel of tests for the diagnosis of APS, according to ISTH guidelines.

On the Critical Care side of the business, sales of the Company's flagship offering , the GEM® Premier™ 4000 analyzer, grew considerably throughout the world due to its ease of use and its Intelligent Quality Management (iQM®) automated quality assurance system.  The new Total Bilirubin assay on the GEM Premier 4000 received 510(K) clearance from the FDA and was launched in the US in 2010, providing rapid, lab-quality results in Neonatal Intensive Care Units.  To better manage a series of GEM Premier 4000 analyzers in a hospital network, IL introduced new GEMweb®Plus 200 Custom Connectivity, offering new features, such as Operator Certification and Advanced Regulatory Management.  Additionally, for a complete critical care testing system, IL introduced GEMdraw Arterial Blood Samplers, featuring GEM EasyDraw and GEM SafetyDraw aspirators and syringes.

"Overall, 2010 was an outstanding year for IL.  We compete in a challenging industry so it is remarkable to see above-market growth, year after year," said Ramon Benet, Senior Vice President, Marketing, Sales & Service at IL.  "Our customers recognize the unique value our products deliver and understand that we are truly passionate about delivering the very best, most innovative products, to ensure optimal patient care.  We never forget that at the end of every single test, is a critically important human life."

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories.  The company's product lines include critical care systems, hemostasis systems and information management systems.  IL's GEM® product offerings, part of the critical care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer.  IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the new ACL TOP 700, the new ACL TOP 700 LAS and the ACL TOP 500 CTS.  IL also offers the new ACL AcuStar™, ACL ELITE® and ELITE PRO, other hemostasis analyzers and the HemosIL® line of reagents.  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.

SOURCE Instrumentation Laboratory